Business
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Recent Corporate Updates
- ZYNRELEF® unit demand increased 68% in the first quarter compared to the prior quarter - - Centers for Medicare and Medicaid Services approved a 3-year
About this update from Heron Therapeutics, Inc.
[{"type":"text","content":"- ZYNRELEF® unit demand increased 68% in the first quarter compared to the prior quarter -\n- Centers for Medicare and Medicaid Services approved a 3-year transitional pass-through status for ZYNRELEF beginning April 1, 2022 to support separate reimbursement outside of the surgical bundle payment for the HOPD setting of care -\n- Oncology Care Franchise net revenue of $22.4 million in Q1 2022, a 13% increase over the prior quarter -\n- Oncology Care Franchise full-year 2022 net revenue expected to be $89 million to $93 million –\nSAN DIEGO, May 9, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three months ended March 31, 2022 and highlighted recent corporate updates.\nRecent Corporate Updates\nAcute Care Franchise\nZYNRELEF:The ZYNRELEF (bupivacaine and meloxicam) extended-release solution New Drug Application (NDA) was approved by the U.S. Food and Drug Administration (FDA) in May 2021. In December 2021, the FDA approved our supplemental New Drug Application (sNDA) for ZYNRELEF, now covering approximately 7 million procedures annually. ZYNRELEF is currently indicated for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures. The FDA also agreed to the contents of a second sNDA, planned for later this year, designed to further expand the indication statement.ZYNRELEF net product sales for the three months ended March 31, 2022 were $1.1 million, which was net of $0.3 million in returns of short-dated ZYNRELEF and a continued reduction of initial distribution channel inventory. Short-dated product returns were due to delays in obtaining initial FDA approval of ZYNRELEF.ZYNRELEF end-user (ambulatory surgical centers (ASC) and hospitals) demand units' sales were 8,673 in the first quarter of 2022, representing an increase of 68% over the prior quarter.During the first three quarters of commercial launch ended March 31, 2022, over 450 unique accounts purchased ZYNRELEF with 80% of those accounts reordering the product.As of April 30, 20...